A new class of drugs is entering myeloma clinical trials. These checkpoint inhibitors take the “brakes” off the immune system so it can do it’s job to kill the myeloma cells. To learn more about how this class of drugs works, click here.
This new drug, called nivolumab, is now being tested in a Phase II clinical trial in combination with dexamethasone and lenalidomide to determine if it can help prevent or postpone smoldering myeloma from progressing to active myeloma.
The trial will enroll 41 patients and will be open in both Beth Israel Deaconess Medical Center and the Dana Farber Cancer Institute in Boston.
Click here to learn more about the clinical trial:Nivolumab, Rev, Dex Smoldering Myeloma Clinical Trial